Red light‐activated depletion of drug‐refractory glioblastoma stem cells and chemosensitization of an acquired‐resistant mesenchymal phenotype
Photochemistry and Photobiology · 2025
DOI: 10.1111/php.13985 ↗At a glance
Journal article in Photochemistry and Photobiology, 2025. Written by Bryan Q Spring and 9 co-authors. Institution: Wellman Center for Photomedicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA. Major MEDLINE topics: Glioblastoma, Neoplastic Stem Cells, Drug Resistance, Neoplasm, Light. 84 references. The full text is freely available in PubMed Central. Funded by: NCI NIH HHS, Massachusetts General Hospital, Canon Medical Systems USA.
Abstract (original language)
Glioblastoma stem cells (GSCs) are potent tumor initiators resistant to radiochemotherapy, and this subpopulation is hypothesized to re‐populate the tumor milieu due to selection following conventional therapies. Here, we show that 5‐aminolevulinic acid (ALA) treatment—a pro‐fluorophore used for fluorescence‐guided cancer surgery—leads to elevated levels of fluorophore conversion in patient‐derived GSC cultures, and subsequent red light‐activation induces apoptosis in both intrinsically temozolomide chemotherapy‐sensitive and ‐resistant GSC phenotypes. Red light irradiation of ALA‐treated cultures also exhibits the ability to target mesenchymal GSCs (Mes–GSCs) with induced temozolomide resistance. Furthermore, sub‐lethal light doses restore Mes–GSC sensitivity to temozolomide, abrogating GSC‐acquired chemoresistance. These results suggest that ALA is not only useful for fluorescence‐guided glioblastoma tumor resection, but that it also facilitates a GSC drug‐resistance agnostic, red light‐activated modality to mop up the surgical margins and prime subsequent chemotherapy.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Wellman Center for Photomedicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
- Department of Physics, Northeastern University, Boston, Massachusetts, USA.
- Healthcare Optics Research Laboratory, Canon USA, Inc., Cambridge, Massachusetts, USA.
- Department of Biomedical Engineering, Tufts University, Medford, Massachusetts, USA.
- Brain Tumor Research Center and Molecular Neurosurgery Laboratory, Department of Neurosurgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
- Division of Health Sciences and Technology, Harvard University and Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
ORCID profiles: Bryan Q Spring, Srivalleesha Mallidi
Funding
- NCI NIH HHS
- Massachusetts General Hospital
- Canon Medical Systems USA
- National Cancer Institute
Cite
APA
Spring, B. Q., Watanabe, K., Ichikawa, M., Mallidi, S., Matsudaira, T., Timerman, D., Swain, J. W. R., Mai, Z., Wakimoto, H., & Hasan, T. (2025). Red light‐activated depletion of drug‐refractory glioblastoma stem cells and chemosensitization of an acquired‐resistant mesenchymal phenotype. Photochemistry and Photobiology. https://doi.org/10.1111/php.13985
Vancouver
Spring BQ, Watanabe K, Ichikawa M, Mallidi S, Matsudaira T, Timerman D, et al. Red light‐activated depletion of drug‐refractory glioblastoma stem cells and chemosensitization of an acquired‐resistant mesenchymal phenotype. Photochemistry and Photobiology. 2025. doi:10.1111/php.13985
BibTeX
@article{Spring2025,
author = {Spring, Bryan Q and Watanabe, Kohei and Ichikawa, Megumi and Mallidi, Srivalleesha and Matsudaira, Tatsuyuki and Timerman, Dmitriy and Swain, Joseph W R and Mai, Zhiming and Wakimoto, Hiroaki and Hasan, Tayyaba},
title = {Red light‐activated depletion of drug‐refractory glioblastoma stem cells and chemosensitization of an acquired‐resistant mesenchymal phenotype},
journal = {Photochemistry and Photobiology},
year = {2025},
doi = {10.1111/php.13985}
}
EUVIMED